HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan
-
With the addition of
Alberta's public plan, Vascepa will be available to more than 90% of Canadians who are eligible and covered by a public or private plan.
Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by
"The PLA with
Approximately 12% of all Canadians live in
ABOUT VASCEPA (ICOSAPENT ETHYL) CAPSULES
Vascepa capsules are the first-and-only prescription treatment comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. Vascepa was approved by
ABOUT
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding HLS, its business and the DRI Healthcare transaction. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's expectations regarding the transaction with DRI Healthcare and the potential benefits to the Company resulting from the transaction; the Company's use of the proceeds from the transaction, including the potential benefits resulting from a reduction in the principal outstanding on the Company's term loan; potential growth opportunities, options for the productive use of capital and HLS's expectations regarding future financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, risks related to HLS' ability to realize the full value of the transaction with DRI Healthcare, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated
REFERENCES
- https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401
- https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000901
SOURCE